Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
Hoyoung Maeng(National Cancer Institute), Jay A. Berzofsky(National Cancer Institute), Svetlana Pack(National Cancer Institute), Lee England(National Cancer Institute), Markku Miettinen(National Institutes of Health), Frederic G. Barr(National Institutes of Health), Jon R. Inglefield(Frederick National Laboratory for Cancer Research), Lauren V. Wood(National Cancer Institute), Seth M. Steinberg(National Institutes of Health), Louis M. Weiner(Georgetown University), Brenda Roberson(National Cancer Institute), David F. Stroncek(Yale University), Wei‐Zen Wei(The Barbara Ann Karmanos Cancer Institute), Kim Dunham(Frederick National Laboratory for Cancer Research), Brittni N. Moore(Johns Hopkins University), Douglas R. Rosing(National Institutes of Health), Masaki Terabe(National Cancer Institute), Hadi Bagheri(National Institutes of Health Clinical Center), Sandhya R. Panch(University of Washington), John C. Morris(Alzheimer's Association), Vandana Sachdev(National Heart Lung and Blood Institute)
Cited by 26
Related Papers
The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
|Clinical Cancer Research|2009|1.4k
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Monoclonal Antibodies in Cancer Therapy
|Antibodies|2020|799
Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer
|Clinical Cancer Research|2005|371